+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Sulfonylureas"

From
From
From
From
Diabetes Drug Intelligence Center 2012-2023 - Product Thumbnail Image

Diabetes Drug Intelligence Center 2012-2023

  • Report
  • May 2024
  • Global
From
From
From
From
Diabetes - Pipeline Insight, 2024 - Product Thumbnail Image

Diabetes - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 200 Pages
  • Global
From
Dementia with Diabetes - Pipeline Insight, 2024 - Product Thumbnail Image

Dementia with Diabetes - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Global Anti-diabetic Drugs Market - Product Thumbnail Image

Global Anti-diabetic Drugs Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
From
Loading Indicator

Sulfonylureas are a class of drugs used to treat type 2 diabetes. They work by stimulating the pancreas to produce more insulin, which helps the body to better process glucose. They are usually taken orally, and are often used in combination with other diabetes medications. Sulfonylureas are generally well-tolerated, but can cause side effects such as hypoglycemia, weight gain, and gastrointestinal upset. The sulfonylureas market is a subset of the larger diabetes drugs market. It is a competitive market, with a range of products available from different manufacturers. The market is expected to grow in the coming years, driven by increasing prevalence of diabetes and the development of new drugs. Some of the major companies in the sulfonylureas market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more